With the principals closely tied to Harvard Medical School and Massachusetts General., Reveal Pharma - also dba as Reveal Pharmaceuticals Inc., - is addressing how to solve major challenges in medical imaging: specifically, how to enable a safer contrast-enhanced MRI imaging without gadolinium plus use of a molecular imaging platform. Currently working as what is described as pre-clinical development stage, principals of the firm have patented a gadolinium-free MRI contrast agent (RVP-001) that was iinvented and develped at MGH and that promises to transform medical imaging by improving safety and deepening insight for contrast enhanced MRI.
